Kerrisdale | Jotup

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Equinix, Harbor Diversified, Altimmune, and UnitedHealth and Encourages Investors to Contact the Firm

Retrieved on:

星期四, 五月 30, 2024

For more information on the Harbor Diversified class action go to: https://bespc.com/cases/HRBR

Key Points:

For more information on the Harbor Diversified class action go to: https://bespc.com/cases/HRBR
Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity and liver diseases.
The Company's lead product candidate is pemvidutide, a glucagon-like peptide-1 ("GLP-1") agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis ("MASH").
On January 6, 2021, UnitedHealth announced an agreement to acquire Change Healthcare (“Change”) and integrate it into its Optum business.
As a result of this disclosure, the price of UnitedHealth stock declined by $27 per share, erasing nearly $25 billion in shareholder value.

ALTIMMUNE, INC. (NASDAQ: ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming Deadline

Retrieved on:

星期二, 五月 28, 2024

Semaglutide, Hepatology, Action Replay, Kerrisdale, News, Obesity, Advertising, Defendant, Court, Weight loss, District court, Complaint, Security (finance)

If you purchased or acquired Altimmune securities, and/or would like to discuss your legal rights and options please visit Altimmune, Inc.

Key Points:

If you purchased or acquired Altimmune securities, and/or would like to discuss your legal rights and options please visit Altimmune, Inc.
If you wish to serve as lead plaintiff, you must move the Court no later than July 5, 2024.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients.
The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines – ALT

Retrieved on:

星期二, 五月 28, 2024

To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.

Key Points:

To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The Company’s lead product candidate is pemvidutide, a glucagon-like peptide-1 (“GLP-1”) agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (“MASH”).
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Equinix, Harbor Diversified, Altimmune, and UnitedHealth and Encourages Investors to Contact the Firm

Retrieved on:

星期日, 五月 26, 2024

For more information on the Harbor Diversified class action go to: https://bespc.com/cases/HRBR

Key Points:

For more information on the Harbor Diversified class action go to: https://bespc.com/cases/HRBR
Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity and liver diseases.
The Company's lead product candidate is pemvidutide, a glucagon-like peptide-1 ("GLP-1") agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis ("MASH").
On January 6, 2021, UnitedHealth announced an agreement to acquire Change Healthcare (“Change”) and integrate it into its Optum business.
As a result of this disclosure, the price of UnitedHealth stock declined by $27 per share, erasing nearly $25 billion in shareholder value.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Equinix, Harbor Diversified, and Altimmune and Encourages Investors to Contact the Firm

Retrieved on:

星期三, 五月 22, 2024

Semaglutide, EQIX, Partnership, MASH, Hepatology, Kerrisdale, News, Obesity, Guggenheim Partners, OTC, Defendant, NASH, P.C, Weight loss, Bloomberg, Complaint

For more information on the Harbor Diversified class action go to: https://bespc.com/cases/HRBR

Key Points:

For more information on the Harbor Diversified class action go to: https://bespc.com/cases/HRBR
Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity and liver diseases.
The Company's lead product candidate is pemvidutide, a glucagon-like peptide-1 ("GLP-1") agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis ("MASH").
On this news, Altimmune's stock price fell $0.87 per share, or 11.98%, to close at $6.39 per share on April 29, 2024.
For more information on the Altimmune class action go to: https://bespc.com/cases/ALT

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines – ALT

Retrieved on:

星期一, 五月 20, 2024

To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.

Key Points:

To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The Company’s lead product candidate is pemvidutide, a glucagon-like peptide-1 (“GLP-1”) agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (“MASH”).
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Malibu Boats, Equinix, Harbor Diversified, and Altimmune and Encourages Investors to Contact the Firm

Retrieved on:

星期五, 五月 17, 2024

Semaglutide, EQIX, Partnership, MASH, Hepatology, Kerrisdale, News, Obesity, Sale, Guggenheim Partners, OTC, Complaint, Defendant, NASH, P.C, Weight loss, Boat, Bloomberg

Then, on April 11, 2024, after the market closed, Malibu Boats revealed that Tommy’s Boats (“Tommy’s”) had filed a complaint against the Company.

Key Points:

Then, on April 11, 2024, after the market closed, Malibu Boats revealed that Tommy’s Boats (“Tommy’s”) had filed a complaint against the Company.
Malibu Boats recognizes a sale when the dealer takes delivery of the boat, regardless of whether it has been sold to the end user.
On this news, Altimmune's stock price fell $0.87 per share, or 11.98%, to close at $6.39 per share on April 29, 2024.
For more information on the Altimmune class action go to: https://bespc.com/cases/ALT

ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Altimmune, Inc. and Encourages Investors to Contact the Firm

Retrieved on:

星期四, 五月 9, 2024

Semaglutide, Person, News, Complaint, Guggenheim Partners, Weight loss, Partnership, P.C, Obesity, NASH, District court, Defendant, Court, Bloomberg, Hepatology, Kerrisdale, Telephone, MASH, Pharmaceutical industry

Investors have until July 5, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points:

Investors have until July 5, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity and liver diseases.
The Company's lead product candidate is pemvidutide, a glucagon-like peptide-1 ("GLP-1") agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis ("MASH").
On November 30, 2023, Altimmune announced topline results from its 48-week MOMENTUM Phase 2 trial evaluating pemvidutide for the treatment of obesity (the "MOMENTUM Trial").

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Altimmune, Inc (ALT)

Retrieved on:

星期二, 五月 7, 2024

Semaglutide, Person, News, Complaint, Guggenheim Partners, Partnership, Obesity, NASH, District court, Defendant, Night-Thoughts, Bloomberg, Kerrisdale

The lawsuit seeks to recover damages for the Company’s investors under the federal securities laws.

Key Points:

The lawsuit seeks to recover damages for the Company’s investors under the federal securities laws.
The Complaint in the lawsuit alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq.
of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected] .

ALTIMMUNE, INC. (NASDAQ: ALT) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Altimmune, Inc.

Retrieved on:

星期二, 五月 7, 2024

Semaglutide, News, Complaint, Weight loss, Obesity, Action Replay, District court, Defendant, Court, Hepatology, Kerrisdale, Advertising, Security (finance)

Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, inclusive (the “Class Period”).

Key Points:

Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, inclusive (the “Class Period”).
If you purchased or acquired Altimmune securities, and/or would like to discuss your legal rights and options please visit Altimmune, Inc.
Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .
The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.